Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dipyridyl SCHEMBL28370248 | 0.80 | KDM4E (0.58) | ALDH1A1FKBP5LMNAP4HTMKDM4E | |
| Dipyridyl SCHEMBL7143241 | 0.80 | KDM4E (0.58) | ALDH1A1FKBP5LMNAP4HTMKDM4E | |
| Catechol SCHEMBL1927483 | 0.79 | ALDH1A1 (0.59) | ALDH1A1FKBP5LMNAKDM4EPOLB | |
| Dipyridyl SCHEMBL3491432 | 0.78 | KDM4E (0.56) | ALDH1A1FKBP5LMNAP4HTMKDM4E | |
| SCHEMBL8978433 | 0.78 | KDM4E (0.50) | ALDH1A1LMNAP4HTMKDM4ECYP1A2 | |
| SCHEMBL29419423 | 0.78 | — | — | |
| SCHEMBL18660488 | 0.78 | — | — | |
| Dipyridyl SCHEMBL3847534 | 0.78 | KDM4E (0.56) | ALDH1A1FKBP5LMNAP4HTMKDM4E | |
| SCHEMBL2355 | 0.78 | — | — | |
| Phenol SCHEMBL7155201 | 0.78 | ALDH1A1 (0.56) | ALDH1A1FKBP5CES2NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858999-B2 | IL-17 receptor A antigen binding proteins | AMGEN K-A, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230124150-A1 | COMPLEMENT FACTOR Bb ANTIBODIES | ALLERGAN, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-4008726-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN, INC. (US) | 2022-06-08 | — | — | EP | disclosed |
| CN-107207585-B | Complement component C5 antibody | 阿勒根公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-3165539-B1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN K A INC (US) | 2021-12-08 | — | — | EP | disclosed |
| US-11180564-B2 | IL-17 Receptor A antigen binding proteins | AMGEN K-A, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210101965-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | XENCOR, INC. | 2021-04-08 | — | — | US | disclosed |
| US-20200362045-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | AMGEN K-A, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200317762-A1 | COMPLEMENT FACTOR Bb ANTIBODIES | ALLERGAN INC (US) | 2020-10-08 | — | — | US | disclosed |
| US-10752678-B2 | Complement component C5 antibodies | ALLERGAN, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-6096728-A | Composition and method for treating inflammatory diseases | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0949931-A1 | COMBINATION THERAPY USING AN IL-1 INHIBITOR FOR TREATING IL-1 MEDIATED DISEASES | AMGEN INC. (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0942740-A2 | COMBINATION THERAPY USING A TNF BINDING PROTEIN FOR TREATING TNF-MEDIATED DISEASES | AMGEN INC. (US) | 1999-09-22 | — | — | EP | disclosed |
| EP-0914431-A2 | TRUNCATED SOLUBLE TUMOR NECROSIS FACTOR TYPE-I AND TYPE-II RECEPTORS | AMGEN INC. (US) | 1999-05-12 | — | — | EP | disclosed |
| CN-1215340-A | Composition comprising interleukin-1 inhibitor and controlled release polymer | AMGEN BULDER INC (US) | 1999-04-28 | — | — | CN | disclosed |
| EP-0904112-A1 | COMPOSITION COMPRISING INTERLEUKIN-1 INHIBITOR AND CONTROLLED RELEASE POLYMER | Amgen Inc., (US) | 1999-03-31 | — | — | EP | disclosed |
| WO-1998024463-A2 | COMBINATION THERAPY USING A TNF BINDING PROTEIN FOR TREATING TNF-MEDIATED DISEASES | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024477-A1 | COMBINATION THERAPY USING AN IL-1 INHIBITOR FOR TREATING IL-1 MEDIATED DISEASES | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998001555-A2 | TRUNCATED SOLUBLE TUMOR NECROSIS FACTOR TYPE-I AND TYPE-II RECEPTORS | AMGEN INC. (US) | 1998-01-15 | — | — | WO | disclosed |
| WO-1997028828-A1 | COMPOSITION COMPRISING INTERLEUKIN-1 INHIBITOR AND CONTROLLED RELEASE POLYMER | AMGEN BOULDER INC. (US) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200362045-A1 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS | IL17A, IL23R, IL15RA | ALDH1A1 4205/4885FKBP5 2038/4885LMNA 2991/4885 |
| US-11858999-B2 | IL-17 receptor A antigen binding proteins | IL17A, IL23R, IL15RA | ALDH1A1 4205/4885FKBP5 2038/4885LMNA 2991/4885 |
| US-11180564-B2 | IL-17 Receptor A antigen binding proteins | IL17A, IL23R, IL15RA | ALDH1A1 4205/4885FKBP5 2038/4885LMNA 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.